Revance Therapeutics is a biotechnology company that develops and commercializes products and treatments for dermatological diseases. The Company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based on a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance’s initial focus is on developing daxibotulinumtoxinA, the Company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The Company’s lead drug candidate, DaxibotulinumtoxinA for Injection, is currently in development for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis, and has the potential to be the first long-acting neurotoxin. 


Type
Public
HQ
Newark, US
Founded
2002
Size (employees)
131 (est)+11%
Revance Therapeutics was founded in 2002 and is headquartered in Newark, US
Report incorrect company information

Key People/Management at Revance Therapeutics

Dan Browne

Dan Browne

Co-Founder, President & Chief Executive Officer
Abhay Joshi

Abhay Joshi

Chief Operating Officer
Lauren Silvernail

Lauren Silvernail

Chief Financial Officer and Chief Business Officer
Todd Zavodnick

Todd Zavodnick

Chief Commercial Officer and President, Aesthetics & Therapeutics
Caryn McDowell

Caryn McDowell

Senior Vice President, General Counsel & Corporate Secretary
Justin Ford

Justin Ford

Vice President, Human Resources and Head of People

Revance Therapeutics Office Locations

Revance Therapeutics has an office in Newark
Newark, US (HQ)
7555 Gateway Blvd
Show all (1)
Report incorrect company information

Revance Therapeutics Financials and Metrics

Revance Therapeutics Financials

Revance Therapeutics's revenue was reported to be $262 k in FY, 2017
USD

Revenue (Q1, 2018)

193 k

Net income (Q1, 2018)

(35 m)

EBIT (Q1, 2018)

(35.7 m)

Market capitalization (21-May-2018)

1.1 b

Closing share price (21-May-2018)

30.4

Cash (31-Mar-2018)

69.2 m
Revance Therapeutics's current market capitalization is $1.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

383 k300 k300 k262 k

Revenue growth, %

(22%)

General and administrative expense

25.1 m29.1 m37.4 m

R&D expense

47.5 m50.4 m80.4 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

158 k75 k75 k75 k75 k75 k75 k75 k75 k75 k75 k193 k

General and administrative expense

6 m6.4 m5.8 m7.5 m7 m7.5 m7.8 m8.6 m13.6 m

R&D expense

7.6 m8.1 m8.6 m9.3 m10.3 m13 m12.4 m15.2 m10.3 m19.4 m18.3 m22.2 m

Operating expense total

11.6 m13 m13.9 m15.3 m16.7 m18.8 m19.8 m24.2 m17.8 m27.2 m26.9 m35.9 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

171 m201.6 m63.5 m282.9 m

Accounts Receivable

155.5 m

Inventories

1.6 m1.6 m7.2 m

Current Assets

172.7 m254 m192.7 m285.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

87.9 m203.3 m187.5 m153.7 m96.4 m90.5 m40.8 m52.7 m130.5 m38.2 m53.7 m69.2 m

Current Assets

91.2 m206.6 m190.9 m155.7 m137.3 m143.5 m238.5 m218.6 m208.7 m197.5 m174.4 m273.4 m

PP&E

15.2 m16.3 m17.4 m19.4 m19.1 m19.3 m19.7 m17.7 m17.4 m11.2 m11.3 m10.1 m

Total Assets

106.9 m223.3 m208.9 m175.7 m171.2 m165.5 m259 m237 m226.9 m209.5 m187.1 m284.8 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.9 m)(73.5 m)(89.3 m)(120.6 m)

Depreciation and Amortization

2.1 m2 m1.4 m1.5 m

Inventories

(999 k)(192 k)(5.6 m)

Accounts Payable

(3.4 m)(692 k)953 k2.6 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(32.2 m)(51.4 m)(19.9 m)(44.5 m)(62.5 m)(27.2 m)(35 m)

Depreciation and Amortization

1.1 m1.6 m344 k699 k1.1 m390 k

Accounts Payable

2.7 m2.7 m2.1 m(938 k)(477 k)552 k279 k200 k5.6 m(1.3 m)

Cash From Operating Activities

(25.5 m)(39.2 m)(15.7 m)(32 m)(46.4 m)(11.1 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Revance Therapeutics News and Updates

Report incorrect company information